Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES.

ABSTRACT:

Background

Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS. This post hoc analysis of ODYSSEY OUTCOMES assessed the effect of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, on the incidence of chest pain not due to recurrent ACS.

Methods

Patients with recent ACS (n = 18,894) and elevated atherogenic lipoprotein levels despite optimized statin therapy were randomized to subcutaneous alirocumab or matching placebo every 2 weeks. Alirocumab dose was adjusted to target low-density lipoprotein cholesterol (LDL-C) 25-50 mg/dL (0.6-1.3 mmol/L) and to avoid consecutive LDL-C <15 mg/dL (0.39 mmol/L). Non-hospitalized chest pain adverse events and ches

SUBMITTER: Geba GP 

PROVIDER: S-EPMC11648769 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature